Category Press Releases

MODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS

MODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season…

Read MoreMODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes, and other serious metabolic diseases

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases  Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to…

Read MoreNovo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes, and other serious metabolic diseases

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The…

Read MoreNovo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial

Johnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution

Johnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution Johnson & Johnson (NYSE: JNJ) (the Company) today announced its subsidiary LTL Management LLC (LTL) will appeal the ruling by the…

Read MoreJohnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the…

Read MoreMerck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.…

Read MorePfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that data from its ophthalmology portfolio will be highlighted in…

Read MoreNew clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility  Pfizer Inc. (NYSE: PFE) today announced the company’s immediate efforts to provide relief and repair the damage caused to its manufacturing facility in Rocky Mount, North Carolina after a…

Read MorePfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility

Medicines and Healthcare Products Regulatory Agency authorizes G SK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

Medicines and Healthcare Products Regulatory Agency authorizes G SK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults GSK plc (LSE/NYSE: GSK) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized Arexvy (respiratory syncytial virus vaccine,…

Read MoreMedicines and Healthcare Products Regulatory Agency authorizes G SK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults